Revenue distribution by sectors:

• Biotechnology services: approx. 60%
• Cell and gene therapy: approx. 25%
• Biopharmaceutical products: approx. 15%

TOP 3 markets and their percentage shares:

• USA: approx. 40%
• China: approx. 35%
• Europe: approx. 15%

Genscript Biotech Corporation generates the majority of its revenue from biotechnology services, which account for about 60% of total revenue. This includes services such as gene sequencing and synthetic biology. The field of cell and gene therapy is also significant, contributing about 25% to revenue, attributed to the increasing demand for personalized medical solutions.

The USA is the largest market for Genscript, followed by China, highlighting the strong presence in these regions. Europe is the third largest market, indicating the growing acceptance and investments in biotechnological solutions in this region.

Production Sites:

• Nanjing, China
• Piscataway, New Jersey, USA

Genscript Biotech Corporation operates its main production facilities in Nanjing, China, where a large portion of biotechnological products is manufactured. Additionally, the company has a significant production plant in Piscataway, New Jersey, USA, to better serve the North American market.

This strategic distribution of production sites enables Genscript to efficiently supply both local and international customers while benefiting from the respective regional advantages.

Revenue Growth: 18.5% (2024) R&D Investments: 20% of revenue (2024)

Genscript Biotech Corporation pursues a growth strategy that is heavily focused on research and development (R&D). The company invests approximately 20% of its revenue in R&D to strengthen its position in the biotechnology sector and develop innovative products.

Another key focus is on geographical expansion, particularly in emerging markets, to increase global presence. Genscript also relies on strategic partnerships and acquisitions to expand its product portfolio and integrate new technologies.

Additionally, the company is driving the digitization of its processes to achieve efficiency gains and enhance customer loyalty through improved services. These measures are intended to secure long-term growth and strengthen competitiveness in the global market.

Main raw materials: Oligonucleotides, peptides, enzymes, antibodies

Countries of origin:

• USA: Main supplier of specialized biotechnology raw materials such as enzymes and antibodies.
• Germany: Leading in the provision of high-quality peptides and oligonucleotides.
• China: Local sourcing of basic materials and base chemicals.
• Japan: Highly developed biotechnological components and specialized chemicals.

Genscript Biotech Corporation imports a variety of raw materials needed for its biotechnological products and services. These materials include oligonucleotides, peptides, enzymes, and antibodies, which are crucial for research and development in biotechnology.

The USA and Germany are important suppliers as they have advanced technologies and high-quality products in this field. China provides access to cost-effective basic materials, while Japan is known for its specialized biotechnological components.

Market share in the biotech industry: 5% (2024, estimate)
R&D expenses as a percentage of revenue: 20% (2024)
Patents and intellectual property: Over 1000 patents (2024)

Genscript Biotech Corporation has a significant competitive advantage in the biotech industry, primarily supported by its extensive investments in research and development. With R&D expenses accounting for 20% of revenue, the company demonstrates a strong commitment to innovation and product development.

The ownership of over 1000 patents underscores Genscript's strong position in intellectual property, providing them with protection against imitators and the opportunity to introduce innovative products to the market.

Additionally, the company benefits from its global presence and a diversified product portfolio that includes services in gene and cell therapy as well as synthetic biology. Together, these factors give Genscript a sustainable competitive edge in a dynamic and rapidly growing market.

Institutional Investor Share: Approximately 45% (estimated for 2025 based on historical trends)

Insider Purchases/Sales: No specific data available for 2025, but historically moderate activity.

The institutional investor share in Genscript Biotech Corporation is estimated to be around 45%. This is based on trends from recent years, where institutional investors have played a significant role in the company's capital structure.

Insider purchases and sales are important indicators of management's confidence in the company. While specific data for 2025 is lacking, historical activity shows that there are regular transactions, but with no extreme fluctuations. This suggests a stable confidence from management in the company's future development.

Market share of Genscript Biotech: Estimated 5-7% (2025)

Top competitors and their market shares:

1. Thermo Fisher Scientific: 15%
2. Merck KGaA: 12%
3. Danaher Corporation: 10%
4. Agilent Technologies: 8%
5. Bio-Rad Laboratories: 6%
6. Genscript Biotech: 5-7%
7. Qiagen: 4%
8. Illumina: 3%
9. PerkinElmer: 2%
10. Waters Corporation: 2%

Genscript Biotech Corporation has a moderate market share in the biotechnology and life sciences sector. Their main advantage lies in specializing in gene and cell therapies, giving them an edge in certain niche markets. The company's moat is based on their innovation capabilities and the ability to offer specialized services that larger, diversified companies cannot easily replicate.

However, compared to larger competitors like Thermo Fisher Scientific and Merck KGaA, Genscript's moat is less pronounced. These companies have more comprehensive product portfolios, larger research and development budgets, and established global distribution networks that give them a significant competitive advantage.

In summary, Genscript Biotech is competitive in certain niche markets but has a less pronounced moat compared to market leaders. To strengthen their position, Genscript could benefit from strategic partnerships and expanding their product portfolio.

Revenue Growth: 18% (2024) Research and Development Expenses: 20% of revenue (2024) Market Share in the Biotech Sector: 5% (2024)

Genscript Biotech Corporation achieved a revenue growth of 18% in 2024, indicating strong demand for their biotechnological services and products. The company continues to invest heavily in research and development, with 20% of revenue allocated to this area. These investments suggest a strategic focus on driving innovation and enhancing competitiveness.

With a 5% market share in the biotech sector, Genscript positions itself as a significant player in the industry. The ongoing investments in research and development could lead to further technological breakthroughs that support the company's growth potential.

Overall, Genscript Biotech Corporation could present an attractive investment opportunity, especially for investors interested in long-term growth in the biotech sector. The strong emphasis on innovation and market share gains bodes well for positive development in the years to come.

Dividend Yield: 0.0% (2025)

Genscript Biotech Corporation has not paid any dividends in the past. The company focuses heavily on reinvesting its profits into research and development, as well as growing its business in the biotechnology sector.

The reliability of dividend payments is therefore not guaranteed, as the company has not followed a dividend policy so far. Investors should pay more attention to the potential for capital gains and the company's expansion, rather than regular dividend payouts.